OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | |
Robson, M. E.; Tung, N.; Conte, P.; Im, S-A; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A. | |
2019 | |
卷号 | 30期号:4页码:558-566 |
关键词 | breast cancer germline BRCA mutation overall survival PARP inhibitor olaparib tolerability |
ISSN号 | 0923-7534 |
DOI | 10.1093/annonc/mdz012 |
URL标识 | 查看原文 |
收录类别 | SCIE ; PUBMED |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6344636 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Robson, M. E.,Tung, N.,Conte, P.,et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J],2019,30(4):558-566. |
APA | Robson, M. E..,Tung, N..,Conte, P..,Im, S-A.,Senkus, E..,...&Domchek, S. M..(2019).OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.,30(4),558-566. |
MLA | Robson, M. E.,et al."OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer".30.4(2019):558-566. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论